Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
Cécile van SteenLorenzo CelicoErik SpaepenTim HagenackerSven Guenther MeuthTobias RuckA Gordon SmithDanielle H BodicoatMaria De FrancescoSergio IannazzoPublished in: Advances in therapy (2024)
Efgartigimod may provide a faster and greater improvement over 26 weeks in quality of life than ravulizumab in adults with AChR-Ab+ gMG. Efgartigimod showed faster improvements in MG-ADL and QMG than ravulizumab.